Cite
APA Citation
Vysotskaia, V., Kaseniit, K. E., Bucheit, L., Ready, K., Price, K., & Johansen Taber, K. (2020). clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Cancer, 126(3), 549–558. http://access.bl.uk/ark:/81055/vdc_100099335488.0x000061